Libo-B (09887): Updated Phase II clinical study data of Varisin (opratuzumab, PD-L1/4-1BB bispecific antibody) combined with chemotherapy for first-line treatment of NSCLC to be presented as an oral presentation at WCLC 2026

Zhito Finance APP News, Limin Pharmaceuticals-B (09887) announced that at the 2026 World Conference on Lung Cancer (WCLC 2026), it presented updated data from a Phase II clinical study of its independently developed investigational drug Vilixin (opartisumab, a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy for first-line treatment of patients with non-small cell lung cancer (NSCLC) in an oral presentation. According to the updated data, unprecedented high response rates were demonstrated, with nearly identical clinical benefits observed in patients with squamous NSCLC who were PD-L1 negative (PD-L1 tumor proportion score (TPS) <1%) and positive (PD-L1 TPS1%), while patients with non-squamous NSCLC and PD-L1 TPS1% achieved deep and durable tumor responses.